Shift Bioscience
CompanyUnited Kingdom
Shift Bioscience develops 2 assets, the furthest preclinical (SB000 in aging). Mostly oligonucleotide; based in the United Kingdom.
- 2
- Assets
- Furthest stage
- Preclinical
- Raised
- £13.2m + US$16m
- 1
- Grant
- 0
- Trials
- 2
- Signals
Pipeline
2Single-gene expression rejuvenates cells without inducing pluripotency.
Preclinical, aging, hearing loss
siRNA knockdown reverses cellular epigenetic aging and ameliorates fibrosis.
Preclinical, Oligonucleotide, liver fibrosis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Funding rounds and grants10
- People12
- Signals2
- Similar companies6